Systemic and Nonrenal Adverse Effects Occurring in Renal Transplant Patients Treated with mTOR Inhibitors
The mammalian target of rapamycin inhibitors (mTOR-I), sirolimus and everolimus, are immunosuppressive drugs largely used in renal transplantation. The main mechanism of action of these drugs is the inhibition of the mammalian target of rapamycin (mTOR), a regulatory protein kinase involved in lymph...
Saved in:
Main Authors: | Gianluigi Zaza, Paola Tomei, Paolo Ria, Simona Granata, Luigino Boschiero, Antonio Lupo |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2013-01-01
|
Series: | Clinical and Developmental Immunology |
Online Access: | http://dx.doi.org/10.1155/2013/403280 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence
by: Goran B. Klintmalm, et al.
Published: (2014-01-01) -
A Decade of Experience Using mTor Inhibitors in Liver Transplantation
by: Jeffrey Campsen, et al.
Published: (2011-01-01) -
Reversion of Hormone Treatment Resistance with the Addition of an mTOR Inhibitor in Endometrial Stromal Sarcoma
by: J. Martin-Liberal, et al.
Published: (2014-01-01) -
mTOR Inhibition: From Aging to Autism and Beyond
by: Matt Kaeberlein
Published: (2013-01-01) -
Differential Reponses of Hematopoietic Stem and Progenitor Cells to mTOR Inhibition
by: Aimin Yang, et al.
Published: (2015-01-01)